Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NanaBis
- Development stage
- Phase 3
- Lead developer
- Medlab Clinical
- Modality
- Small Molecules
- Administration
- Oromucosal
01
Overview
NanaBis is a proprietary cannabinoid-based pharmaceutical formulation developed for medical use, particularly in the management of pain. It is an oromucosal spray containing a 1:1 ratio of tetrahydrocannabinol (THC) and cannabidiol (CBD), both derived from cannabis. The mechanism of action involves THC acting as a partial agonist at the cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2), leading to modulation of neurotransmitter release, analgesia, and other central nervous system effects. CBD acts as an antagonist or modulator at these receptors and also interacts with other targets such as serotonergic receptors and vanilloid receptors, contributing to its therapeutic profile. NanaBis has been investigated primarily for cancer-related pain but may have potential applications in other chronic pain conditions.
- Brand names
- NanaBis
- Other names
- THC:CBD 1:1 oro-buccal sprayd9-THC & CBD formulation
02
Targets
CNR1 (Cannabinoid receptor 1)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on NanaBis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NanaBis.